Adaptin Bio (APTN) Cash & Current Investments (2022 - 2026)

Adaptin Bio's Cash & Current Investments history runs 5 years deep, the most recent figure standing at $301309.0 for Q1 2026.

• In Q1 2026, Cash & Current Investments fell 87.31% year-over-year to $301309.0; the TTM figure through Mar 2026 stood at $301309.0 (down 87.31% YoY), while the FY2025 annual figure was $459174.0, up 1247.14% from the prior year.
• Cash & Current Investments came in at $301309.0 for Q1 2026 at Adaptin Bio, down from $459174.0 in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $2.4 million in Q1 2025 to a low of $322.0 in Q3 2024.
• A 5-year average of $394976.6 and a median of $23776.0 in 2024 frame the typical range for Cash & Current Investments.
• Across the five-year window, Cash & Current Investments jumped 179741.3% in 2025 and plunged 87.31% in 2026, its largest moves.
• Adaptin Bio's Cash & Current Investments stood at $500.0 in 2022, then jumped by 850.8% to $4754.0 in 2023, then surged by 616.98% to $34085.0 in 2024, then soared by 1247.14% to $459174.0 in 2025, then tumbled by 34.38% to $301309.0 in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $301309.0, $459174.0, and $579089.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison